BeiGene Ltd Stock Research

Market Summary

USD219.71+0.69

Market Closed

0.32%

BGNE Alerts

1 major insider sales recently.
Big jump in Revenue (Y/Y)
Losses in recent quarter

BGNE Stock Price

BGNE RSI Chart

BGNE Valuation

Market Cap

298.0B

Price/Earnings (Trailing)

-148.7

Price/Sales (Trailing)

210.43

EV/EBITDA

-159.63

Price/Free Cashflow

-163.53

BGNE Price/Sales (Trailing)

BGNE Profitability

EBT Margin

-138.50%

Return on Equity

-45.71%

Return on Assets

-31.41%

Free Cashflow Yield

-0.61%

BGNE Fundamentals

BGNE Revenue

Revenue (TTM)

1.4B

Revenue Y/Y

77.63%

Revenue Q/Q

-1.94%

BGNE Earnings

Earnings (TTM)

-2.0B

Earnings Y/Y

24.61%

Earnings Q/Q

20.13%

Price Action

52 Week Range

118.18280.62

(Low)(High)

Last 7 days

-2.2%

Last 30 days

-3.2%

Last 90 days

-2.8%

Trailing 12 Months

8.5%

BGNE Financial Health

Current Ratio

3.55

BGNE Investor Care

Shares Dilution (1Y)

1.60%

Diluted EPS (TTM)

-1.49

Peers (Alternatives to BeiGene)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	298.0B	1.4B	-3.25%	8.54%	-148.7	210.43	20.37%	-37.45%
ABBV	279.9B	58.1B	4.88%	1.38%	23.64	4.82	3.30%	2.55%
REGN	87.7B	12.2B	9.61%	20.63%	20.21	7.2	-24.26%	-46.28%
VRTX	80.8B	8.9B	6.80%	24.91%	24.32	9.05	17.91%	41.84%
ALNY	23.5B	1.0B	-5.53%	16.05%	-20.81	22.69	22.88%	-32.64%
SRPT	11.5B	933.0M	2.93%	61.85%	-16.28	12.27	32.93%	-67.99%
UTHR	10.1B	1.9B	-9.77%	22.96%	13.92	5.23	14.88%	52.86%
MID-CAP
MDGL	4.2B	504.0K	-19.59%	144.55%	-14.38	2.5K	-66.53%	-22.12%
RARE	2.6B	363.3M	-18.37%	-45.49%	-3.74	7.28	3.39%	-55.81%
BPMC	2.6B	204.0M	1.49%	-34.21%	-4.68	12.78	13.30%	13.44%
MRTX	2.3B	12.4M	-15.06%	-52.42%	-3.05	181.9	-	-27.34%
SMALL-CAP
CPRX	1.7B	214.2M	4.81%	93.98%	20.42	7.92	52.10%	110.42%
MGNX	412.2M	151.9M	1.98%	-27.23%	-3.44	2.71	96.19%	40.75%
CRBP	28.6M	-	145.52%	1270.00%	-0.67	19.11	-77.61%	7.22%
CYTK	3.1M	94.6M	-20.08%	-11.44%	-0.01	0.03	34.30%	-80.65%

Financials for BeiGene

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	13.3%	1,415,921,000	1,249,805,000	1,068,617,000	877,037,000	1,176,283,000
S&GA Expenses	1.8%	1,277,852,000	1,255,369,000	1,201,704,000	1,102,590,000	990,123,000
R&D Expenses	1.0%	1,640,508,000	1,624,970,000	1,550,544,000	1,528,428,000	1,459,239,000
EBITDA	9.1%	-1,842,279,000	-2,025,714,000	-1,926,567,000	-1,870,492,000	-
EBITDA Margin	19.7%	-1.30	-1.62	-1.80	-2.13	-
Earnings Before Taxes	7.4%	-1,961,037,000	-2,116,876,000	-1,998,716,000	-1,921,702,000	-1,438,588,000
EBT Margin	18.2%	-1.38	-1.69	-1.87	-2.19	-
Interest Expenses	76.2%	52,480,000	29,779,000	14,790,000	-1,507,000	-15,757,000
Net Income	6.8%	-2,003,815,000	-2,149,158,000	-2,029,716,000	-1,948,594,000	-1,457,816,000
Net Income Margin	17.7%	-1.42	-1.72	-1.86	-2.18	-
Free Cahsflow	9.1%	-1,822,053,000	-2,005,322,000	-1,897,517,000	-1,926,065,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-5.2%	6,379	6,726	7,378	8,021	8,536
Current Assets	-9.4%	5,207	5,749	6,346	6,948	7,614
Cash Equivalents	-7.8%	3,870	4,197	4,531	4,347	4,376
Inventory	-2.9%	282	291	262	246	243
Net PPE	24.1%	846	682	633	625	588
Liabilities	-3.6%	1,996	2,071	2,076	2,136	2,403
Current Liabilities	4.1%	1,469	1,411	1,398	1,376	1,600
LT Debt, Current	-25.5%	329	441	381	407	2,725
LT Debt, Non Current	593.3%	1,443	208	1,241	1,278	202
Shareholder's Equity	-5.8%	4,383	4,655	5,197	5,774	6,133
Retained Earnings	-6.7%	-7,080	-6,635	-5,971	-5,400	-5,076
Additional Paid-In Capital	0.8%	11,541	11,452	11,357	11,268	11,191
Accumulated Depreciation	5.0%	150	143	138	124	-
Shares Outstanding	0.5%	1,356	1,350	1,350	1,335	1,335

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	11.2%	-1,496	-1,686	-1,620	-1,660	-1,298
Share Based Compensation	5.2%	303	288	277	260	241
Cashflow From Investing	-6.1%	1,077	1,148	966	559	641
Cashflow From Financing	-100.5%	-18.97	3,476	3,465	3,518	3,637

Risks for BGNE

What is the probability of a big loss on BGNE?

100%

Probability that BeiGene stock will be more than 20% underwater in next one year

66.2%

Probability that BeiGene stock will be more than 30% underwater in next one year.

34.6%

Probability that BeiGene stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BGNE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if BeiGene was unfortunately bought at previous high price.

Drawdowns

Returns for BGNE

Cumulative Returns on BGNE

34.2%

7-Year Cumulative Returns

6.8%

5-Year Cumulative Returns

19.3%

3-Year Cumulative Returns

What are the long-term rolling returns for BGNE?

FIve years rolling returns for BeiGene.

Annualized Returns

Which funds bought or sold BGNE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-10	BAILLIE GIFFORD & CO	added	6.19	316,951,000	749,714,000	0.78%
2023-03-06	OLD MISSION CAPITAL LLC	new	-	5,767,270	5,767,270	0.16%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-0.45	74,000	193,000	-%
2023-02-28	Voya Investment Management LLC	sold off	-100	-631,000	-	-%
2023-02-24	National Pension Service	sold off	-100	-1,288,660	-	-%
2023-02-24	SRS Capital Advisors, Inc.	unchanged	-	100	1,100	-%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	1,980	1,980	-%
2023-02-21	MACQUARIE GROUP LTD	added	2.31	2,119,060	5,284,060	0.01%
2023-02-17	TRUIST FINANCIAL CORP	new	-	249,852	249,852	-%
2023-02-16	HARBOUR INVESTMENTS, INC.	added	10.34	2,038	7,038	-%

Latest Funds Activity

Are funds buying BGNE calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own BGNE

No. of Funds

BeiGene News

Schedule 13G FIlings of BeiGene

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	hhlr advisors, ltd.	10.9%	147,043,058	SC 13D/A
Feb 13, 2023	capital international investors	8.2%	110,215,170	SC 13G/A
Feb 10, 2023	oyler john	5.1%	70,026,397	SC 13G/A
Aug 16, 2022	hhlr advisors, ltd.	10.9%	147,035,258	SC 13D/A
Feb 14, 2022	oyler john	5.1%	69,558,605	SC 13G/A
Feb 11, 2022	capital international investors	7.8%	104,036,177	SC 13G/A
Feb 11, 2022	beigene, ltd.	5.1%	69,558,605	SC 13G/A
Feb 11, 2022	invesco ltd.	5.6%	39,028,821	SC 13G
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 16, 2021	capital international investors	7.6%	89,894,623	SC 13G/A

BGNE Fair Value

BeiGene fair value in different scenarios

The table shows the Fair Value estimates for BeiGene for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	0.97 -99.56%	1.20 -99.45%	1.95 -99.11%	3.33 -98.48%	6.11 -97.22%
Current Inflation	0.95 -99.57%	1.15 -99.48%	1.81 -99.18%	2.99 -98.64%	5.35 -97.56%
Very High Inflation	0.93 -99.58%	1.10 -99.50%	1.64 -99.25%	2.59 -98.82%	4.48 -97.96%

Historical BeiGene Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of BeiGene

View All Filings

Date Filed	Form Type	Document
Mar 20, 2023	4	Insider Trading
Mar 10, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Feb 27, 2023	10-K	Annual Report
Feb 27, 2023	8-K	Current Report
Feb 14, 2023	SC 13D/A	13D - Major Acquisition
Feb 13, 2023	SC 13G/A	Major Ownership Report
Feb 10, 2023	SC 13G/A	Major Ownership Report
Feb 10, 2023	SC 13G/A	Major Ownership Report
Jan 31, 2023	8-K	Current Report

Latest Insider Trading transactions for BGNE

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-16	Wang Xiaodong	gifted	-	-	-67,444	-
2023-03-08	Wang Xiaodong	acquired	8,792	0.13	67,635	-
2023-03-08	Wang Xiaodong	sold	-15,287,300	226	-67,635	-
2023-03-01	Wang Julia Aijun	sold	-82,391	240	-343	chief financial officer
2023-01-12	Wang Xiaodong	sold	-1,302,580	260	-5,000	-
2023-01-11	Wang Xiaodong	sold	-631,647	252	-2,500	-
2023-01-10	Wang Xiaodong	sold	-400,152	250	-1,600	-
2023-01-10	OYLER JOHN	sold	-1,689,160	248	-6,797	chief executive officer
2023-01-10	OYLER JOHN	sold	-3,378,290	248	-13,594	chief executive officer
2023-01-09	Wang Xiaodong	sold	-225,000	250	-900	-

About BeiGene

John V. Oyler

www.beigene.com

8200

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Beijing, China.

BGNE Income Statement

2022-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues
Total revenues	$ 1,415,921	$ 1,176,283	$ 308,874
Expenses
Cost of sales - product	286,475	164,906	70,657
Research and development	1,640,508	1,459,239	1,294,877
Selling, general and administrative	1,277,852	990,123	600,176
Amortization of intangible assets	751	750	846
Total expenses	3,205,586	2,615,018	1,966,556
Loss from operations	(1,789,665)	(1,438,735)	(1,657,682)
Interest income (expense), net	52,480	(15,757)	1,998
Other (expense) income, net	(223,852)	15,904	37,490
Loss before income taxes	(1,961,037)	(1,438,588)	(1,618,194)
Income tax expense	42,778	19,228	10,397
Net loss	(2,003,815)	(1,457,816)	(1,628,591)
Less: net loss attributable to noncontrolling interests	0	0	(3,617)
Net loss attributable to BeiGene, Ltd.	$ (2,003,815)	$ (1,457,816)	$ (1,624,974)
Net loss per share attributable to BeiGene, Ltd., basic (in dollars per share)	$ (1.49)	$ (1.21)	$ (1.50)
Net loss per share attributable to BeiGene, Ltd., diluted (in dollars per share)	$ (1.49)	$ (1.21)	$ (1.50)
Weighted-average shares outstanding, basic (in shares)	1,340,729,572	1,206,210,049	1,085,131,783
Weighted-average shares outstanding, diluted (in shares)	1,340,729,572	1,206,210,049	1,085,131,783
Net loss per American Depositary Share (ADS), basic (in dollars per share)	$ (19.43)	$ (15.71)	$ (19.47)
Net loss per American Depositary Share (ADS), diluted (in dollars per share)	$ (19.43)	$ (15.71)	$ (19.47)
Weighted-average ADSs outstanding, basic (in shares)	103,133,044	92,785,388	83,471,676
Weighted-average ADSs outstanding, diluted (in shares)	103,133,044	92,785,388	83,471,676
Product revenue, net
Revenues
Total revenues	$ 1,254,612	$ 633,987	$ 308,874
Collaboration revenue
Revenues
Total revenues	$ 161,309	$ 542,296	$ 0

BGNE Balance Sheet

2022-12-31

CONSOLIDATED BALANCE SHEETS ¥ in Thousands, $ in Thousands	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Current assets:
Cash and cash equivalents	$ 3,869,564	$ 4,375,678
Short-term restricted cash	196	328
Short-term investments	665,251	2,241,962
Accounts receivable, net	173,168	483,113
Inventories	282,346	242,626
Prepaid expenses and other current assets	216,553	270,173
Total current assets	5,207,078	7,613,880
Long-term restricted cash	5,277	6,881
Property, plant and equipment, net	845,946	587,605
Operating lease right-of-use assets	109,960	117,431
Intangible assets, net	40,616	46,679
Other non-current assets	170,413	163,049
Total non-current assets	1,172,212	921,645
Total assets	6,379,290	8,535,525
Current liabilities:
Accounts payable	294,781	262,400
Accrued expenses and other payables	467,352	558,055
Deferred revenue, current portion	213,861	187,414
Tax payable	25,189	21,395
Operating lease liabilities, current portion	24,041	21,925
Research and development cost share liability, current portion	114,335	120,801
Short-term debt	328,969	427,565
Total current liabilities	1,468,528	1,599,555
Non-current liabilities:
Long-term debt	209,148	202,113
Deferred revenue, non-current portion	42,026	220,289
Operating lease liabilities, non-current portion	34,517	43,041
Deferred tax liabilities	15,996	14,169
Research and development cost share liability, non-current portion	179,625	269,561
Other long-term liabilities	46,095	54,234
Total non-current liabilities	527,407	803,407
Total liabilities	1,995,935	2,402,962
Commitments and contingencies
Equity:
Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,356,140,180 and 1,334,804,281 shares issued and outstanding as of December 31, 2022 and 2021, respectively	135	133
Additional paid-in capital	11,540,979	11,191,007
Accumulated other comprehensive (loss) income	(77,417)	17,950
Accumulated deficit	(7,080,342)	(5,076,527)
Total equity	4,383,355	6,132,563
Total liabilities and equity	$ 6,379,290	$ 8,535,525